Oral Session 3-11B AML: FLT3 mutations

[OS3-11B-6] Phase 2 results of quizartinib in Japanese patients with FLT3-ITD mutated relapsed/refractory AML

Takeshi Takahashi¹, Kensuke Usuki², Kosei Matsue³, Hitoshi Ohno⁴, Toru Sakura⁵, Ryota Imanaka⁶, Masato Murakami⁷, Shoichi Ohwada⁷, Taiga Takagi⁷, Sakura Sakajiri⁸ (1.Gifu Municipal Hospital, Gifu, Japan, 2.NTT Medical Center Tokyo, Tokyo, Japan, 3.Kameda Medical Center, Kamogawa, Japan, 4.Tenri Hospital, Tenri, Japan, 5.Saiseikai Maebashi Hospital, Maebashi, Japan, 6.Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan, 7.Daiichi Sankyo Co., Ltd., Tokyo, Japan, 8.Juntendo University Urayasu Hospital, Urayasu, Japan)